文献速递静脉血栓栓塞

美国食品药品监督管理局安全警告后下腔静脉滤器按适应证使用的更新趋势:2010年至2019年十年分析

Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019.
PubMed 文献 · J Endovasc Ther · 2023-03-01

该研究基于美国全国住院患者样本数据库,分析2010至2019年下腔静脉滤器(IVCF)置入趋势。共置入823 717枚滤器,其中78.3%用于静脉血栓栓塞症(VTE)治疗,21.7%用于预防。总置入量从2010年129 616枚降至2019年58 465枚,总下降率为-8.4%;2014至2019年下降率(-11.6%)高于2010至2014年(-7.2%)。作者认为2014年FDA重申安全警告可能对全国IVCF使用产生额外影响,且不同医院类型和地区间存在差异。

要点

  • 2010至2019年IVCF总置入量从129 616枚降至58 465枚,总下降率为-8.4%。
  • 2014至2019年下降率(-11.6%)高于2010至2014年(-7.2%)。
  • VTE治疗和预防适应证的置入量分别以-7.9%和-10.2%的速率下降。

核心结论

  • 2014至2019年IVCF置入下降率高于2010至2014年,提示2014年FDA重申安全警告对国家IVCF使用有额外影响。
  • VTE治疗和预防适应证的IVCF使用在不同医院教学类型、位置和地区间存在差异。
  • 作者认为需要统一IVCF置入指南以规范临床实践,从而减少观察到的地区和医院差异及潜在的IVC滤器过度使用。

研究设计与样本

  • 利用全国住院患者样本数据库,通过国际疾病分类第九版临床修改版和第十版代码识别2010至2019年下腔静脉滤器置入。
  • 将IVCF置入按适应证分为VTE治疗(有VTE诊断且存在抗凝禁忌)和预防(无VTE)。
  • 使用广义线性回归分析使用趋势。

主要发现

  • 研究期间共置入823 717枚IVCF,其中644 663枚(78.3%)用于VTE治疗,179 054枚(21.7%)用于预防适应证。
  • 两类患者的中位年龄均为68岁。
  • 所有适应证的IVCF总置入量从2010年129 616枚降至2019年58 465枚,总下降率为-8.4%。
  • 2014至2019年下降率为-11.6%,高于2010至2014年的-7.2%。
  • 2010至2019年,VTE治疗和预防适应证的IVCF置入分别以-7.9%和-10.2%的速率下降;城市非教学医院下降率最高(VTE治疗-17.2%,预防-18.0%),东北地区医院下降率最高(VTE治疗-10.3%,预防-12.5%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Overall inferior vena cava filter (IVCF) utilization has decreased in the United States since the 2010 US Food and Drug Administration (FDA) safety communication. The FDA renewed this safety warning in 2014 with additional mandates on reporting IVCF-related adverse events. We evaluated the impact of the FDA recommendations on IVCF placements for different indications from 2010 to 2019 and further assessed utilization trends by region and hospital teaching status. METHODS: Inferior vena cava filter placements between 2010 and 2019 were identified in the Nationwide Inpatient Sample database using the associated International Classification of Diseases, Ninth Revision, Clinical Modification, and Tenth Revision codes. Inferior vena cava filter placements were categorized by indication for venous thromboembolism (VTE) "treatment" in patients with VTE diagnosis and contraindication to anticoagulation and "prophylaxis" in patients without VTE. Generalized linear regression was used to analyze utilization trends. RESULTS: A total of 823 717 IVCFs were placed over the study period, of which 644 663 (78.3%) were for VTE treatment and 179 054 (21.7%) were for prophylaxis indications. The median age for both categories of patients was 68 years. The total number of IVCFs placed for all indications decreased from 129 616 in 2010 to 58 465 in 2019, with an aggregate decline rate of -8.4%. The decline rate was higher between 2014 and 2019 than between 2010 and 2014 (-11.6% vs -7.2%). From 2010 to 2019, IVCF placement for VTE treatment and prophylaxis trended downward at rates of -7.9% and -10.2%, respectively. Urban nonteaching hospitals saw the highest decline for both VTE treatment (-17.2%) and prophylactic indications (-18.0%). Hospitals located in the Northeast region had the highest decline rates for VTE treatment (-10.3%) and prophylactic indications (-12.5%). CONCLUSION: The higher decline rate in IVCF placements between 2014 and 2019 compared with 2010 and 2014 suggests an additional impact of the renewed 2014 FDA safety indications on national IVCF utilization. Variations in IVCF use for VTE treatment and prophylactic indications existed across hospital teaching types, locations, and regions. CLINICAL IMPACT: Inferior vena cava filters (IVCF) are associated with medical complications. The 2010 and 2014 FDA safety warnings appeared to have synergistically contributed to a significant decline in IVCF utilization rates from 2010 - 2019 in the US. IVC filter placements in patients without venous thromboembolism (VTE) declined at a higher rate than VTE. However, IVCF utilization varied across hospitals and geographical locations, likely due to the absence of universally accepted clinical guidelines on IVCF indications and use. Harmonization of IVCF placement guidelines is needed to standardize clinical practice, thereby reducing the observed regional and hospital variations and potential IVC filter overutilization.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Olanipekun T, Ritchie C, Abe T, et al. Updated Trends in Inferior Vena Cava Filter Use by Indication in the United States After Food and Drug Administration Safety Warnings: A Decade Analysis From 2010 to 2019. J Endovasc Ther. 2023. PMID: 36859812. doi:10.1177/15266028231156089

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。